MSLE Satellos Bioscience Inc.
Satellos Bioscience Inc. (MSLE) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.35 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.7% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Satellos Bioscience Inc.
Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.
Sector
Healthcare
Industry
Biotechnology